SEQUENCE LISTING

<110> Vicuron Pharmaceuticals Inc, <120> Antibiotic 107891, its factors Al and A2, pharmaceutically acceptable salts and composition, and use thereof <130> G69277 <160> 1 <170> PatentIn version 3.1 <210> <211> 1443 <212> DNA Microbispora sp. ATCC PTA-5024 <213> <220> <221> misc feature <222> (1)..(1443)gene segment specifying 16S rRNA <400> 1 gacgaacgct_ggcggcgtgc_ttaacacatg_caagtcgagc_ggaaaggccc_ttcggggtac_____60_ tcgagcggcg aacgggtgag taacacgtga gtaacctgcc cctgactctg ggataagcct 120 gggaaaccgg gtctaatacc ggatatgaca catggtcgca tgagcggtgt gtggaaagtt 180 ttttcggttg gggatgggct cgcggcctat cagcttgttg gtggggtgat ggcctaccaa 240 300 ggcgacgacg ggtagccggc ctgagagggc gaccggccac actgggactg agacacggcc 360 cagactccta cgggaggcag cagtggggaa tattgcgcaa tgggcggaag cctgacgcag cgacgccgcg tgggggatga cggccttcgg gttgtaaacc tctttcagca gggacgaagt 420 tgacgtgtac ctgtagaaga agcgccggct aactacgtgc cagcagccgc ggtaatacgt 480 agggcgcaag cgttgtccgg aattattggg cgtaaagagc tcgtaggtgg cttgttgcgt 540 600 ctgccgtgaa agcccgtggc ttaactacgg gtctgcggtg gatacgggca ggctagaggc tggtaggggc aagcggaatt cctggtgtag cggtgaaatg cgcagatatc aggaggaaca 660 ccggtggcga aggcggcttg ctgggccagt tctgacgctg aggagcgaaa gcgtggggag 720 cgaacaggat tagataccct ggtagtccac gctgtaaacg ttgggcgcta ggtgtggggg 780 tettecaega tteetgtgee gtagetaaeg cattaagege eeegeetggg gagtaeggee 840 gcaaggctaa aactcaaagg aattgacggg ggcccgcaca agcggcggag catgttgctt 900 aattogacgo aacgogaaga acottaccaa ggtttgacat acacoggaaa gototggaga 960

1020

PAGE 2

agatgttggg	ttaagtcccg	caacgagege	aacccttgtt	ccatgttgcc	agcacgccct	1080
ttggggtggt	ggggactcat	gggagactgc	cggggtcaac	tcggaggaag	gtggggatga	1140
cgtcaagtca	tcatgcccct	tatgtcttgg	gctgcaaaca	tgctacaatg	gtcggtacag	1200
agggttgcga	tgccgtgagg	tggagcgaat	ccctaaaagc	cggtctcagt	tcggattggg	1260
gtctgcaact	cgaccccatg	aagtcggagt	cgctagtaat	cgcagatcag	caacgctgcg	1320
gtgaatacgt	tcccgggcct	tgtacacacc	gcccgtcacg	tcacgaaagt	cggcaacacc	1380
cgaagcccgt	ggcccaacca	cttgtggggg	gagcggtcga	aggtggggct	ggcgattggg	1440
acq						1443